[ad_1]
Meritz Values(4,365 -0.80%)On the 18th, SK Bioscience believes that the stock price will have a huge advantage even after trading as it has extensive bullish power (momentum). We do not present a rating and target price. SK Biosciences will be listed on the stock exchange on this day.
SK Bioscience is SK Chemicals in 2018(318,000 + 6.35%)It is a company established by dividing the Korean vaccine business division. It is engaged in the distribution and sale of vaccines, consignment production (CMO) and consignment development production (CDMO). AstraZeneca and NovaVax have signed a CMO / CDMO contract for the COVID-19 vaccine and a technology transfer contract has been signed for the national supply of the NovaVax vaccine.
Researcher Jiha Kim said, “The performance of the CMO and CDMO business, taking into account the global average unit price and profit structure, is expected to be 4.969 billion won this year and 739.5 billion won next. anus”. ” he said.
It is also believed to be ensuring long-term growth engines by developing its own Corona 19 vaccine and premium vaccine. SK Bioscience is developing two candidates for the COVID-19 vaccine using a synthetic antigen method. These are phase 1 and phase 1 and 2 clinical trials, respectively. It is planning to proceed with a global phase 3 clinical trial with an article within this year, with phase 1 results expected to be announced in the first half of the year.
Additionally, Sanofi and the next-generation pneumococcal vaccine are in phase 2 clinical trials worldwide. The goal is to become the best drug in its class on the 7 trillion won pneumococcal vaccine market.
Researcher Kim said: “SK Bioscience can offer you a premium as a manufacturer of Corona 19 vaccines.”
Like SK Biopharm, we believe that a positive flow in the share price can be expected from the incorporation of the major indices. Due to the low proportion of shares outstanding (16% when the one-month protection deposit is canceled), it may be difficult to add Morgan Stanley Capital International (MSCI) in May, but if the market capitalization remains at KRW 5 trillion or more in June, it can be included It is that it is high.
SK Bioscience’s market capitalization is 4,972.5 billion won based on the public offering price of 65,000 won. The quantity available for circulation is 11.6% of the total stock.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
